The Federal Trade Commission's showdown with America's largest pharmacy benefit managers just got a timeout. Federal regulators hit pause on their administrative case, signaling that settlement talks might actually be going somewhere.
On January 20, the FTC formally stayed its case against six respondents, including some of the biggest names in the business: UnitedHealth Group Inc.'s (UNH) OptumRx division, CVS Health Corp.'s (CVS) CVS Caremark, Cigna Corp.'s (CI) Express Scripts, plus Evernorth Health Inc., Medco Health Services Inc., and Ascent Health Services LLC.
The FTC approved a 14-day suspension that pushes back everything—discovery, filing deadlines, decision dates, and the evidentiary hearing that was supposed to happen soon but is now delayed until July 1. Oral arguments on the PBMs' motion to dismiss got bumped from January 22 to February 5. Every respondent in the case gets the same breathing room.
How We Got Here
This lawsuit launched back in September 2024, when the FTC accused the dominant PBMs of unfair and anti-competitive practices that allegedly pumped up insulin list prices. The regulators' argument? PBMs wielded their market power and rebate structures like a lever, essentially pushing drugmakers to raise prices.
Then things escalated. In January 2025, the FTC dropped a second interim staff report with some eye-popping findings: PBMs were slapping massive markups on specialty generic drugs for cancer, HIV, and other serious conditions—sometimes marking them up by hundreds or even thousands of percent.
Political Heat and Media Scrutiny
Earlier this month, President Donald Trump rolled out what he dubbed "The Great Healthcare Plan," specifically calling out PBM "kickbacks" as a major culprit behind soaring drug costs.
The pressure isn't just coming from government regulators. A January 2025 investigation by Hunterbrook Media alleged that CVS Health, UnitedHealth, and Cigna are using shell companies to hide billions of dollars in profits—money that could theoretically be redirected toward lower patient prices.
Put it all together—the enforcement pause, the political spotlight, and the investigative heat—and it looks like the FTC's case against pharmacy benefit managers might be heading toward a negotiated resolution. Whether that means a settlement or just more delays remains to be seen, but the next two weeks could tell us a lot.
